Featured Post

Negative Symptoms and Xanomeline-Trospium: What Trials and Practice Data Can and Cannot Show

October 5, 2026

Negative-symptom scores fell on xanomeline-trospium in schizophrenia trials, but how much reflects treatment, especially in stable illness, remains unclear.
 Read More

Other top stories

Larger Response in Prominent Negative Symptoms, but No Evidence of Superiority

September 30, 2026

Two Investigational Paths in GAD: Company-Reported Results on DT120 ODT and SNTX-2643

September 29, 2026

Generalized Anxiety Disorder After 65: What the Screening Evidence Does and Does Not Cover

September 23, 2026

The latest news on Psychopharmacology

Could Psilocybin Help Parkinson’s Patients, Too?

Could Psilocybin Help Parkinson’s Patients, Too?
Administration, Professional Groups Trade Barbs Over Psychotropics

Administration, Professional Groups Trade Barbs Over Psychotropics
RE104 Offers a Revolutionary Approach to Postpartum Depression

RE104 Offers a Revolutionary Approach to Postpartum Depression
Weekly Mind Reader: Clinicians Tackle Psychedelics

Weekly Mind Reader: Clinicians Tackle Psychedelics

Other stories

A Recovery Estimate Reflects Symptoms and Function, Not What the Patient Reports

September 16, 2026

A Rising Quality of Life Score Does Not Mean Improved Function

September 16, 2026

Who Gets Excluded from Psychedelic Trials in GAD, and Why

September 16, 2026

Measurement-Based Care in Generalized Anxiety Disorder

September 16, 2026

Similar Outcomes With 2-Week and 4-Week Tapers to Xanomeline-Trospium

September 10, 2026

Xanomeline-Trospium and EPS: Low Rates Across Trials, Comparative Data Remain Limited

September 10, 2026

Insightful. Evidence-based. Human-centered.

Listen Now
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe